Private Equity Hub -- Evolva SA, a Swiss biotech company that uses a genetic chemistry platform to developer small molecule drugs, has raised CHF16 million ($15.37m) in additional Series B funding. This brings the round total to CHF44 million ($42.27m), including an initial CHF28 million close in October. Backers include Wellington Partners, Aravis, Auriga Partners and Vinci Capital – Renaissance PME. The investment was part of Evolva’s reverse merger with Switzerland-listed Arpida Ltd. In other Evolva news, the company’s Indian subsidiary secured a CHF5 million funding commitment from Ventureast Trustee Company Pte Ltd.
